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REVIEW CURRENTOPINION Metabolomics: is it useful for inflammatory
bowel diseases?opyright © Lippincott Will
www.co-gastroenterology.coma b cMartin Storr , Hans J. Vogel , and Rudolf SchichoPurpose of review
The assessment of metabolite profiles in biofluids has become a powerful method for the detection of
biomarker molecules and disease mechanisms. This review outlines the recent advances in the use of
metabolomic techniques to study inflammatory bowel diseases (IBDs).
Recent findings
The last few years have seen an increase in the studies of experimental and human IBD focusing on the
search for small metabolites, such as amino acids, bases, and tricarboxylic acid cycle intermediates.
Experimental methods for the screening of metabolites in serum, urine, fecal extracts, and colon tissue
include 1H NMR spectroscopy, gas chromatography–mass spectrometry, and liquid chromatography
methods. Several studies demonstrate that IBD patients and healthy individuals, as well as the IBD subtypes,
can be distinguished using metabolic profiling. Metabolomic data of fecal extracts and urine have revealed
disruptions in bacterial populations, findings that are indicative of a possible involvement of the
microbiome in the development of IBDs.
Summary
Metabolites from biofluids can be detected in IBDs by different experimental methods that allow successful
separation of IBD subtypes from healthy cohorts. Knowledge of a unique metabolomic fingerprint in IBDs
could be useful for diagnosis, treatment, and detection of disease mechanisms.
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Several serologic markers for inflammatory bowel
diseases (IBDs) are currently available. Although they
are invaluable as an adjunct to endoscopic and radio-
logic findings, they are less helpful in differentiating
between the two subtypes of IBDs, that is, Crohn’s
disease and ulcerative colitis, or in categorizing
patients with indeterminate colitis. Thus, biomarkers
that clearly discriminate between these two subtypes
and between remission and flare-ups would be
enormously useful for clinical practice. Additionally,
changes in the concentrations of metabolites may
reveal important clues about severity and activity of
IBDs. Such information is important to support diag-
nosis and to provide an insight into the underlying
pathophysiological mechanisms of IBDs, which are
far from clear at present.Correspondence to Rudolf Schicho, PhD, Institute of Experimental and
Clinical Pharmacology, Medical University of Graz, Universitätsplatz 4,
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Techniques of metabolomic research have an
advantage of being extremely sensitive and ofiams & Wilkins. Unauthoallowing to perform experiments in a cost-effective
high-throughput manner. Common technologies
used for metabolomics include (with increasing
sensitivity) 1H NMR spectroscopy, gas chromatog-
raphy–mass spectrometry (GC–MS), and liquid
chromatography–mass spectrometry (LC–MS). Ion
cyclotron resonance-Fourier transform mass spec-
trometry (ICR-FT/MS) with ultrahigh mass resol-
ution has allowed for the separation of thousands
of masses that correspond to small but com-
plex metabolites [1], whereas another advancedrized reproduction of this article is prohibited.
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KEY POINTS
 Metabolic profiling of biofluids combined with
multivariate analysis is extremely useful for
discriminating between IBD patients and
healthy individuals.
 IBD subtypes can be discriminated by metabolic
profiling of serum and plasma.
 Through metabolic profiling, we are able to identify
biomarkers of IBDs as well as components of
disease mechanisms.
Metabolomics and inflammatory bowel disease Storr et al.high-resolution technique (ultra-performance
liquid chromatography coupled with electrospray
ionization quadrupole time-of-flight MS) has
recently been employed in experimental IBDs [2
&
].
Measuring metabolites by NMR and MS gener-
ates a large amount of data which needs to be
organized by multivariate analysis methods in order
to extract the important information. Thus, meta-
bolomic data are usually interpreted by statistical
methods such as principal component analysis
(PCA) and orthogonal partial least squares (OPLS)
projections [3]. OPLS is based on projection to latent
structures (PLS), a pattern recognition method that
reduces numerous collinear variables (metabolites)
to a few subsets to demonstrate their interdepend-
ence. OPLS-discriminant analysis (DA) maximizes
the independence of variables, resulting in better
separation of data between cohorts and therefore in
better discrimination of diseased individuals from
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FIGURE 1. Score plots of OPLS-DA coefficients from plasma me
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analysis.
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INFLAMMATORY BOWEL DISEASES
Over the years, several mouse models of IBDs have
been used to measure differences in the metabolic
profiles of serum, urine, fecal extracts, and gut
tissues between diseased and nondiseased animals.
These models include the interleukin-10/ knock-
out model [4–7], the TNFDARE/WT model that
mimics Crohn’s-disease-like ileitis with great
similarity [8
&
], and the dextran sulfate sodium
(DSS)-induced experimental colitis model that
largely resembles ulcerative colitis [9
&
,10,11].





], and LC–MS [8
&
] were employed to profile
metabolites in these models. Despite having lower
sensitivity, 1H NMR spectroscopy may be preferred
to MS because of its higher reproducibility [12
&
]
and the application of ‘targeted’ metabolomics.
‘Targeted’ (quantitative) metabolic profiling in
1H NMR spectroscopy, compared with the tradi-
tional spectral binning, significantly improves the
chances for the discovery of disease-related bio-
markers. The technique involves the analysis of a
large group of compounds whose characteristics
(e.g., individual NMR spectra) are established and
stored in a database library. From the complex
mixture of individual metabolite spectra in the
biofluid, the spectra in the database can be used
to identify and quantify the targeted metabolites
[13]. Quantitative metabolic profiling has already
been used in two different mouse models of colitis
to discriminate between diseased vs. nondiseased
states [4,10] and in serum, plasma, and urine of IBD
patients [14
&&
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Inflammatory bowel diseaseChanges in metabolic profiles: a possible
clue to pathogenesis?
Changes in the metabolism of cholesterol, triglyce-
rides, and phospholipids that were demonstrated in
a mouse model of Crohn’s disease [8
&
], highlight the
importance of inflammatory lipid mediators as
potential biomarkers of IBDs. Helicobacter hepaticus
Rag2/ mice, another model of IBD, revealed sig-
nificant differences between diseased and non-
diseased animals in compounds involved in
tryptophan, fatty acid, and purine metabolism, as
well as in methionine–homocysteine and tricarbox-
ylic acid (TCA) cycles [15
&
]. Some of these changes,
such as those in tryptophan metabolism and TCA
cycle, were also observed in other studies of exper-
imental IBD [5,10]. In IL-10/ knockout mice, a
model in which mice develop a spontaneous colitis,
NMR-based metabolic profiling was studied over
time and revealed many changes in molecules
related to energy household including lactate, pyr-
uvate, and citrate [4,5]. In a DSS colitis model,
metabolic profiles were measured by GC–MS to
differentiate between acute colitis and the resol-
ution phase, suggesting that metabolomics could
be useful for determining disease progression [9
&
].
NMR has also been successfully used to monitor the
effects of antibiotics on the urine and fecal meta-
bolic profiles of mice [16].METABOLOMICS AND HUMAN
INFLAMMATORY BOWEL DISEASE
The use of metabolomic analysis in human IBD
arose from the need to improve diagnosis and differ-
entiation of IBD subtypes and to classify indetermi-
nate colitis. Simultaneously, the method offered a
new approach to screen for small molecules that
might play a role in disease mechanisms. A non-
invasive approach of diagnosing IBDs may also be
preferable over endoscopy which is not without risk,
although serious complications are reportedly low
[17]. Noninvasive fecal and serologic markers with
variable specificity and sensitivity for IBDs are
already in use. Among them, lactoferrin, calprotec-
tin, PMN-elastase, and CRP are used to differentiate
active from inactive IBD as well as from irritable
bowel syndrome (IBS) with quite good diagnostic
accuracy (e.g. 83% for lactoferrin in ulcerative colitis
and 81.4% for calprotectin in Crohn’s disease [18]).
Other serologic markers such as anti-Saccharomyces
cerevisiae (ASCA) and perinuclear antineutrophil
cytoplasmic antibodies (pANCAs) or the more
experimental anti-CBir1 and anti-OmpC are less
sensitive for IBDs [19], although a combination of
these markers has recently shown high predictive
value in distinguishing IBD subtypes [20
&
].opyright © Lippincott Williams & Wilkins. Unautho
380 www.co-gastroenterology.comTo date, 1H NMR spectroscopy has been
employed most widely to characterize activity and
severity of human IBDs. Studies have been per-
formed on biofluids such as serum, plasma, urine,
and fecal extracts as well as on biopsies, isolated
colonocytes, and lymphocytes of IBD patients and
were compared to matched healthy persons. These
studies have primarily focused on small and non-
complex molecules, such as amino acids and
related metabolites, on TCA cycle intermediates,
and on metabolites involved in fatty acid and purine
metabolism. Differences in metabolic profiles were







,24,25] as well as between





variate statistical models are the best choice to
discriminate patients from healthy individuals,
Balasubramanian et al. [26] were able to detect sig-
nificant shifts using univariate statistical methods in
a variety of metabolites of the colonic mucosa in
patients with Crohn’s disease and ulcerative colitis
in comparison to healthy persons or IBD patients
in remission.
With regard to confounding factors, medication
does not seem to influence the metabolomic data
very much [14
&&
,24,25], although in one study IBD
patients who were on TNF-a antibodies had differ-
ent urinary metabolic profiles than those without
TNF-a antibody treatment [22]. Inclusion of IBD
patients with bowel resections may also confound
statistical outcome [22].URINARY METABOLOMICS
In human IBDs, the type of biofluid investigated
may have a significant impact on the metabolic
profile. For instance, intersubject variability is
reported to be higher in urine than in serum [27].
Several studies have demonstrated that urinary
metabolites are more influenced by environmental
cues (diet, diurnal rhythms, age, sex, and cultural
influences) than serum or plasma metabolites
[28–30]. Despite these variations, urinary meta-
bolomic data may provide an important insight into
changes within the bacterial population that colo-
nize the gut, information that may be of high
relevance. Metabolites of gut bacteria can usually
be detected in urine [31]. In fact, a lot has already
been learned about the role of the gut microbiome
through various metabolomic studies [32
&&
].
The gut microbiome is intricately involved in
the pathogenesis of IBDs [33] and dysbiosis may
occur either as a cause or as a consequence of
the disease [34]. An altered population in the
microbiome may thus lead to an altered urinary
metabolic profile. Williams et al. [25] investigatedrized reproduction of this article is prohibited.
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Metabolomics and inflammatory bowel disease Storr et al.the metabolites in longitudinal samples of urine
from Crohn’s disease and ulcerative colitis patients
by 1H NMR spectroscopy using multivariate analysis
and PLS-DA. Their model of evaluation distinguished
well between IBD patients and healthy individuals,
and also between ulcerative colitis and Crohn’s dis-
ease patients. Significant decreases in hippurate, a
metabolite that derives from microbiota, were found
in IBD patients. Similarly, good separation of patients
with IBD from healthy individuals by 1H NMR spec-
troscopy and multivariate analysis were reported by
two other groups [14
&&
,22]. They also noticed low
hippurate levels in urine of IBD patients, suggesting
that hippurate may be a biomarker candidate. The
findings are of high interest as hippurate levels were
recently shown to correlate with the presence of
Clostridia in the gut [35] and Clostridia bacteria have
been found widely in Crohn’s disease patients [34].
Nevertheless, more data are necessary concerning the
specificity of such markers as NMR can, for instance,
reveal changes in hippurate, citrate, 2-oxoglutarate
and creatinine already after slight changes in weight,
suggesting that these compounds may represent
general stress markers rather than specific biomarkers
[36]. Other studies [14
&&
,22,24] failed to distinguish
between ulcerative colitis and Crohn’s disease
through urinary metabolic profiling, emphasizing
the influence of environmental variation in urinary
metabolomics and the multifactorial nature of IBDs.
In fact, IBD shows high variations in phenotype and
severity, and ulcerative colitis is easily confounded
with colonic Crohn’s disease and indeterminate
colitis [37].METABOLOMICS OF SERUM AND
PLASMA
Schicho et al. [14
&&
] showed that quantitative meta-
bolic profiling of serum and plasma by 1H NMR
spectroscopy and multivariate analysis discriminated
between ulcerative colitis and Crohn’s disease
patients, albeit with a weaker predictability than
between healthy and ulcerative colitis/Crohn’s dis-
ease patients. These observations were recently con-
firmed in serum in a comparable study [21
&
]. In a
mouse model of colitis, serum metabolomics
measured by the same method were clearly different
between diseased and nondiseased animals [10].
Another group that analyzed the plasma of patients
with IBD with the aim to investigate differences in
metabolites demonstrated that amino acid profiles
evaluated by a novel statistical data modeling
(aminogram) discriminated between IBD and
healthy individuals, and between ulcerative colitis
and Crohn’s disease [38
&&
]. Statistical indices also
correlated well with disease activity, indicating thatCopyright © Lippincott Williams & Wilkins. Unau
0267-1379  2013 Wolters Kluwer Health | Lippincott Williams & Wilkmetabolic profiles of amino acids could be useful in
monitoringdisease activity during progression of IBD
[38
&&
]. A further report using GC/MS showed that IBD
patients with either ulcerative colitis or Crohn’s dis-
ease could be readily distinguished from each other
on the basis of amino acids and TCA cycle-related
molecules [39]. Altogether, these studies demon-
strate that metabolic serum and plasma profiles
can separate between patients with IBD and healthy
controls as well as between the IBD subtypes irrespec-
tive of the technique, favoring the use of serum and
plasma for the reliable measurement of metabolic
profiles. However, analysis of serum may not provide
us with information on important changes in the
population of the gut microbiota.METABOLOMICS OF FECAL EXTRACTS
The possible involvement of microbiota in the patho-
genesis of IBD has also led to an interest in the use of
metabolic profiling of fecal extracts for diagnosis and
biomarkerdetection [40]. Work by Marchesi et al. [41]
has already highlighted that NMR-based metabolic
profiles in human fecal extracts of IBD patients show
decreased levels of short-chain fatty acids and that
profiles are significantly distinct from healthy indi-
viduals. Recently, another study using 1H NMR spec-
troscopy of fecal samples showed clear separation of
ulcerative colitis patients from control cohorts,
whereas the model was less successful in distinguish-
ing between IBS patients and healthy controls [23
&
].
NMR spectra in this study correlated well between gut
microbiota profiles as well as fecal metabolite com-
position, indicating that metabolomics of fecal
samples not only discriminates between diseased
and healthy individual, but reveals valuable insight
into disturbances of gut bacteria [23
&
]. Fecal extracts
may therefore provide important clues on how the
microbiome contributes to the pathology of IBD.
Jansson et al. [1] used ICR-FT/MS with an ultrahigh
mass resolution in fecal extracts of Crohn’s disease
patients. They were able to measure thousands of
masses that differentiated between healthy and dis-
eased individuals. Compounds of amino acid path-
ways and bile acid metabolism, saturated and
unsaturated fatty acids, and arachidonic acid were
among the discriminating metabolites. This points
again to the important role of inflammatory lipid
mediators in IBD and to their use in metabolic
profiles for classifying IBD patients and healthy indi-
viduals.METABOLOMICS OF COLON TISSUE
Biopsies from colon tissue represent another source
material to study metabolomics in IBD. Sharma et al.thorized reproduction of this article is prohibited.
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Inflammatory bowel disease[42] assessed macroscopically involved and unin-
volved mucosa of the colon from IBD patients by
1H NMR spectroscopy and detected similar meta-
bolic profiles in these biopsies, whereas another
study reported differences between biopsies from
IBD patients and healthy individuals with regard
to amino acids, membrane components, and lactate
[26]. Using multivariate analysis, Bjerrum et al. [24]
demonstrated that active ulcerative colitis can be
separated from inactive ulcerative colitis by meta-
bolic profiles of biopsies and isolated colonocytes.
Interestingly, these workers showed that 20% of
inactive ulcerative colitis patients had metabolic
profiles similar to those with active ulcerative colitis.
The authors suggested that the ulcerative-colitis-like
profiles in these patients could have indicated
pathogenic changes that occurred prior to or
immediately after flare-ups instead of representing
subclinical inflammation [43].CONCLUSION
Metabolic profiling of biofluids from IBD patients
represents a powerful approach for the detection of
biomarkers and underlying mechanisms of IBD. In
addition, the biofluids investigated can hold differ-
ent information on IBD, that is, whereas metabolic
profiles of serum and plasma allow reproducible
separation of patients with IBD from healthy con-
trols and additionally allow separation of IBD sub-
types, urinary metabolic profiles are harder to
interpret because of a higher susceptibility of urine
composition to environmental variation. However,
as gut microbiota are regarded as possible important
players in IBD pathogenesis, urinary and fecal
metabolic profiles may provide important infor-
mation on disease development, perpetuation,
and progression. A recent study shows that fecal
transplants significantly improved recurrent Clos-
tridium difficile infection [44], suggesting such
treatment might also be useful in alleviating or
curing IBD, or maintaining remission. It would be
very interesting to follow these patients in future
studies following such treatment in order to deter-
mine whether their serum, urine, and fecal extract
profiles returned to normal and to explore the
prognostic value of metabolomic analysis in this
setting. Whatever technique and biofluid are going
to be used for metabolic profiling of IBD patients in
the future, metabolomics certainly will become an
important adjunct in the clinical assessment and
management of IBDs.Acknowledgements
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